Cardiff Oncology, Inc.
Cardiff Oncology, Inc.
Your view on CRDF
Overview
What the company does, where it operates, and who runs it.
About Cardiff Oncology, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark Erlander
- Headquarters
- 11055 Flintkote Avenue, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark Erlander
- Headquarters
- 11055 Flintkote Avenue, San Diego, CA, US
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.
Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers.
The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Cardiff Oncology, Inc., and the rating behind it. CRDF last traded at $1.21; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cardiff Oncology, Inc.. Starting points for Cardiff Oncology, Inc.: EPS -$0.59, beta 1.46 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cardiff Oncology, Inc.. Cardiff Oncology, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cardiff Oncology, Inc.. Trailing twelve-month EPS for Cardiff Oncology, Inc. stands at -$0.59. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cardiff Oncology, Inc.. Cardiff Oncology, Inc. has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cardiff Oncology, Inc. valued side by side against its closest peers. Cardiff Oncology, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Cardiff Oncology, Inc., and how their positions are changing. At a $93.3M market value, institutional positions materially move Cardiff Oncology, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Cardiff Oncology, Inc. executives and directors. Shares of Cardiff Oncology, Inc. have traded between $1.90 and $5.64 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cardiff Oncology, Inc.. Cardiff Oncology, Inc. is a $93.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cardiff Oncology, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cardiff Oncology, Inc.. Coverage tracks Cardiff Oncology, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.